secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001517022-23-000034
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia extends Chief Legal Officer's departure date to March 29, 2024, with possible further extension
--------------------------------------------------------------------------------

- Nicole R. Hadas, SVP, Chief Legal Officer and Corporate Secretary, will now separate on March 29, 2024 (previously October 6, 2023).
- Under certain conditions, termination date may extend to September 22, 2024.
- This is the fourth amendment to the original May 2022 retention and separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000034/0001517022-23-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000034/akba-20231006.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer